TAK 114

Drug Profile

TAK 114

Alternative Names: Meisoindigo; Natura-α; TAK-114

Latest Information Update: 23 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Natrogen Therapeutics International
  • Developer Natrogen Therapeutics International; Takeda Pharmaceuticals International GmbH
  • Class Anti-inflammatories; Indoles; Small molecules
  • Mechanism of Action Cytokine modulators; Regulatory T-lymphocyte modulators; STAT3 transcription factor inhibitors; Th17 cell modulators; Transcription factor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Prostate cancer; Systemic lupus erythematosus; Ulcerative colitis

Most Recent Events

  • 16 Dec 2016 Biomarkers information updated
  • 10 May 2016 Discontinued - Phase-I for Ulcerative colitis in Japan (PO)
  • 10 May 2016 Discontinued - Phase-II for Ulcerative colitis in European Union, USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top